Drugs / Infanrix-IPV/Hib
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT00964028 | Dec 2009 → Apr 2010 | diphtheria, haemophilus infectious disease, poliomyelitis, tetanus | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Infanrix-IPV/Hib | “This study will evaluate the safety and reactogenicity of Infanrix-IPV/Hib given as a three-dose primary vaccination course” NCT00964028 ↗ |
| Modality | Vaccine | “Infanrix-IPV/Hib™ vaccine” NCT00964028 ↗ |
| Route | Intramuscular | “administered intramuscularly into the upper right side of the thigh” NCT00964028 ↗ |